Summary
4.62 0.10(2.10%)10/04/2024
Fennec Pharmaceuticals Inc (FENC)
Fennec Pharmaceuticals Inc (FENC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.76 | -11.25 | -17.15 | -20.57 | -57.70 | -28.89 | -0.75 | 275.26 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 4.62 | |
| Open | 4.58 | |
| High | 4.70 | |
| Low | 4.55 | |
| Volume | 57,054 | |
| Change | 0.08 | |
| Change % | 1.76 | |
| Avg Volume (20 Days) | 76,995 | |
| Volume/Avg Volume (20 Days) Ratio | 0.74 | |
| 52 Week Range | 4.50 - 11.92 | |
| Price vs 52 Week High | -61.28% | |
| Price vs 52 Week Low | 2.56% | |
| Range | 0.76 | |
| Gap Up/Down | -0.04 | |
Fundamentals | ||
| Market Capitalization (Mln) | 141 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 10.80 | |
| Book Value | 0.7310 | |
| Earnings Per Share | -0.6280 | |
| EPS Estimate Current Quarter | -0.1700 | |
| EPS Estimate Next Quarter | 0.7800 | |
| EPS Estimate Current Year | 0.2500 | |
| EPS Estimate Next Year | -0.6600 | |
| Diluted EPS (TTM) | -0.6280 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -96.2471 | |
| Return on asset (TTM) | -0.3404 | |
| Return on equity (TTM) | -0.6437 | |
| Revenue TTM | 170,000 | |
| Revenue per share TTM | 0.0070 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 170,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.6492 | |
| Revenue Enterprise Value | 520.9261 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 26,006,900 | |
| Shares Float | 19,844,009 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 16.94 | |
| Institutions (%) | 45.35 | |
09/05 06:56 EST - globenewswire.com
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences.
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences.
08/13 14:20 EST - seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (FENC) Q2 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Robert Andrade - CFO Jeffrey Hackman - CEO and Board Member Conference Call Participants Chase Knickerbocker - Craig Hallum Naureen Quibria - Capital One Securities Raghuram Selvaraju - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals Second Quarter 2024 Earnings and Corporate Update Conference Call.
08/13 08:26 EST - zacks.com
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.
Adherex Technologies Inc. (FENC) Reports Q2 Loss, Lags Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.21 per share a year ago.
08/13 06:05 EST - globenewswire.com
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m.
Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m.
08/06 16:31 EST - globenewswire.com
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024
Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference
08/05 06:26 EST - globenewswire.com
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr.
Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director
~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced the appointment of Mr.
07/29 06:15 EST - investorplace.com
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!
Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money.
3 Dirt-Cheap Stocks Under $10 That Could EXPLODE!
Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money.
07/01 06:00 EST - globenewswire.com
Fennec Pharmaceuticals Announces Management Change
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.
Fennec Pharmaceuticals Announces Management Change
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership team as Chief Operating Officer.
06/25 16:35 EST - globenewswire.com
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 25, 2024.
05/14 13:15 EST - seekingalpha.com
Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Financial Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Chase Knickerbocker - Craig Hallum Michael Okunewitch - Maxim Group Raghuram Selvaraju - HC Wainwright Operator Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call.
Fennec Pharmaceuticals Inc. (FENC) Q1 2024 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (NASDAQ:FENC ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Rosty Raykov - Chief Executive Officer and Director Robert Andrade - Chief Financial Officer Adrian Haigh - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Chase Knickerbocker - Craig Hallum Michael Okunewitch - Maxim Group Raghuram Selvaraju - HC Wainwright Operator Good morning, ladies and gentlemen. And welcome to the Fennec Pharmaceuticals' First Quarter 2024 Earnings and Corporate Update Conference Call.
05/14 08:16 EST - zacks.com
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.23 per share a year ago.
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.41 per share, missing the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $0.23 per share a year ago.
05/14 06:03 EST - globenewswire.com
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~
05/07 18:15 EST - globenewswire.com
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
05/02 11:06 EST - zacks.com
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Adherex Technologies Inc. (FENC) Report Negative Q1 Earnings? What You Should Know
Adherex Technologies (FENC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
03/21 08:16 EST - zacks.com
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Tops Revenue Estimates
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.26 per share a year ago.
03/21 06:00 EST - globenewswire.com
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~
03/19 11:16 EST - zacks.com
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up
Fennec (FENC) signs a licensing deal with Nordine, granting the latter rights to Pedmarqsi in the EU, Australia and New Zealand to treat cisplatin-induced hearing loss. The stock rises 11.4%.
03/19 09:51 EST - zacks.com
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Adherex Technologies Inc. (FENC) is on the Move, Here's Why the Trend Could be Sustainable
Adherex Technologies Inc. (FENC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
03/19 06:01 EST - globenewswire.com
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
03/17 21:00 EST - globenewswire.com
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI® , the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced hearing loss in pediatric patients with localized, non-metastatic solid tumors